Bio-Path Holdings, Inc. (NASDAQ:BPTH) Short Interest Up 189.4% in December

Bio-Path Holdings, Inc. (NASDAQ:BPTH) was the target of a significant growth in short interest in December. As of December 31st, there was short interest totalling 250,000 shares, a growth of 189.4% from the December 15th total of 86,400 shares. Currently, 5.8% of the shares of the stock are short sold. Based on an average daily volume of 3,070,000 shares, the short-interest ratio is currently 0.1 days.

Institutional Investors Weigh In On Bio-Path

A hedge fund recently bought a new stake in Bio-Path stock. Armistice Capital LLC purchased a new position in Bio-Path Holdings, Inc. (NASDAQ:BPTH) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned approximately 4.66% of Bio-Path at the end of the most recent quarter. Institutional investors own 5.74% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, StockNews.com assumed coverage on shares of Bio-Path in a research note on Saturday. They issued a “sell” rating on the stock.

Bio-Path Trading Down 1.7 %

Shares of BPTH opened at $0.93 on Tuesday. The stock has a 50 day moving average price of $0.90 and a 200 day moving average price of $1.15. Bio-Path has a one year low of $0.59 and a one year high of $10.78.

Bio-Path Company Profile

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.